Recent studies suggest that some misunderstanding around lead-time bias continues to persist in the literature.
A recent study documents a downward trend in melanoma incidence in adolescents and young adults, but experts disagree about the causes.
Many individual metabolite changes are often common among cancers and not specific to RCC, making the identification of diagnostic or prognostic biomarkers difficult.
Research shows how cancer cells can act like bacteria and adapt to increase their chances of survival.
The chance of missing a disease-causing variant can be as high as 100% across some groups.
To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.
Findings underscore the limited generalizability of clinical trial results to patients in the real world.
As more and more patients undergo immunotherapy treatments, understanding possible side effects on cognitive function is an important research gap.
Are patients who have received fewer prior medications better candidates for the receipt of CAR-T therapies?
